Journal of Pharmacy And Bioallied Sciences

REVIEW ARTICLE
Year
: 2022  |  Volume : 14  |  Issue : 2  |  Page : 72--80

Mini-Review on the efficacy and safety of pitavastatin: “The novel seventh statin gaining momentum”


Azza Ramadan1, Asim Ahmed Elnour2 
1 AAU Health and Biomedical Research Center, Al Ain University, Al Ain, United Arab Emirates
2 AAU Health and Biomedical Research Center, Al Ain University, Al Ain, United Arab Emirates; Program of Clinical Pharmacy, College of Pharmacy, Abu Dhabi Campus-Al Ain University, Abu Dhabi-, UAE

Correspondence Address:
Dr. Asim Ahmed Elnour
Program of Clinical Pharmacy, College of Pharmacy, Al Ain University, Abu Dhabi Campus, Abu Dhabi
UAE

Background: Recently, a plethora of events have affected the statin arena such as muscle-induced myalgia, myopathy, myositis, rare rhabdomyolysis, and new-onset diabetes. The latest statin pitavastatin has emerged with descent stamina (optimum efficacy and improved safety). Objective: The objective of the current review is to explore the pros and cons of pitavastatin as a novel second-generation statin in terms of efficacy and safety that delineate its clinical utility. Methods: The review was conducted via EBSCO hosted Medline search (AL Ain University, UAE subscription) for relevant English written literature articles containing “pitavastatin” as the primary search term “pitavastatin and safety;” “pitavastatin and efficacy” and “pitavastatin and safety and randomized clinical trials;” and “pitavastatin and efficacy and randomized clinical trials.” Results: The number of articles containing the word “pitavastatin” as the primary search term used was (n = 901). The next retrieves MeSH term was “pitavastatin and safety” (n = 99) and then “pitavastatin and efficacy” (n = 132). Furthermore, narrowing down the search by adding study design terms revealed: “pitavastatin and safety and randomized clinical trials,” (n = 10) and “pitavastatin and efficacy and randomized clinical trials” (n = 13). Combining the two main searches (safety and efficacy) has yielded 23 items, of which 15 articles were satisfying the current mini-review criteria. The prominent efficacy of pitavastatin was depicted by the increase in high-dense lipoprotein cholesterol and a decrease in low-dense lipoprotein cholesterol as illustrated by the clinical trials in the results and discussions section. The safety was enlightened with a very low propensity to cause new-onset diabetes and a low tendency for statin-induced muscular adverse events. Conclusion: Pitavastatin might be suitable for patients with the acute coronary syndrome (ACS), metabolic syndrome, and patients with diabetes. We highly recommend rational individualization for the selection of statin, especially in patients with diabetes and/or with ACS.


How to cite this article:
Ramadan A, Elnour AA. Mini-Review on the efficacy and safety of pitavastatin: “The novel seventh statin gaining momentum”.J Pharm Bioall Sci 2022;14:72-80


How to cite this URL:
Ramadan A, Elnour AA. Mini-Review on the efficacy and safety of pitavastatin: “The novel seventh statin gaining momentum”. J Pharm Bioall Sci [serial online] 2022 [cited 2022 Aug 17 ];14:72-80
Available from: https://www.jpbsonline.org/article.asp?issn=0975-7406;year=2022;volume=14;issue=2;spage=72;epage=80;aulast=Ramadan;type=0